Plant for the production of medicines. Russian pharmaceutical manufacturers. Important features of the industry

The largest Russian pharmaceutical companies earned from 15 billion rubles (PJSC Pharmstandard) to 182 billion rubles (JSC NPK Katren) in annual revenue in 2015.

The last two years of 2015 and 2016, the Russian pharmaceutical industry shows a noticeable growth - more than 20% in 2016, according to the statement of the Minister of Industry and Trade of the Russian Federation Denis Manturov.

At a briefing held at the Russian Ministry of Industry and Trade, Deputy Minister Sergei Tsyb said that the best evidence of the growth of the domestic pharmaceutical industry is that the American pharmaceutical giants are outraged: it is difficult for them to break into Russian market, as they are being forced out by large pharmaceutical companies in Russia. We have analyzed and prepared the Top 7 largest Russian pharmaceutical holdings in terms of revenue for 2015.

Pharmstandard

Legal address: Moscow

Date of registration: 1996

Founders: Minin Alexander Nikolaevich, Kuznetsov Igor Gennadievich.

CEO: Kuznetsov Igor Gennadievich

• Authorized capital: RUB 1,000,012.86
• Fixed assets: 153,955 thousand rubles
• Revenue: 21,191,811
• Accounts receivable: 2,667,522 thousand rubles
• Accounts payable: 6,961,274 thousand rubles.
• Net profit: 1,042,833 thousand rubles
• Net assets: 2,646,595 thousand rubles
• TIN - 7731241639

https://www.euro-service.ru/

Sia International

Joint Stock Company "Sia International LTD" is engaged in the sale of medicines and medical devices pharmacies and medical institutions.

It has warehouse complexes in Moscow and more than 35 cities of Russia. Their total area is more than 200 thousand square meters.

Legal address: Moscow city

Date of registration: 1995

Founders: CJSC "Rink", Rudinsky Igor Feliksovich.

CEO: Demkin Alexander Yurievich

• Authorized capital: 20,000,000 rubles
• Fixed assets: 5,624,687 thousand rubles.
• Revenue: RUB 59,438,184 thousand
• Accounts receivable: 13,597,841 thousand rubles.
• Accounts payable: 20,209,002 thousand rubles.
• Net profit: -3,111,114 thousand rubles
• Net assets: 2,908,224 thousand rubles
• TIN - 7714030099

Sources: official website: https://mpharma.ru/, extract from the Unified State Register of Legal Entities, Rosstat (data financial reporting according to RAS for 2015).

R-Pharm

R-Pharm Joint Stock Company specializes in high-tech medicines. The company is currently working towards large-scale investment projects.

Creates production base within the framework of the state strategy for the development of the Russian pharmaceutical industry until 2020.

Legal address: Moscow

Date of registration: year 2001

Founders: Repik Alexey Evgenievich

CEO: Ignatiev Vasily Gennadievich

• Authorized capital: 28,400 rubles.
• Fixed assets: 2,119,636 thousand rubles
• Revenue: 62,204,014 thousand rubles
• Accounts receivable: 13,435,674 thousand rubles.
• Accounts payable: 30,682,362 thousand rubles
• Net profit: RUB 8,608,010 thousand
• Net assets: 24,205,818 thousand rubles
• TIN - 7726311464

Sources of information: official website: http://r-pharm.com, extract from the Unified State Register of Legal Entities, Rosstat (data of financial statements according to RAS for 2015).

Growth

Closed Joint-Stock Company"Growth". In total, the pharmaceutical group "Rosta" includes 4 companies: "Rosta" (is engaged in the distribution of medicines), "Rosta-marketing" (trade marketing), "Rainbow Production" (plant for the production of solid drugs), United Pharmacy Chain, which includes the companies "Rainbow", "First Aid", "Ladushka".

Legal address: Moscow region, city of Podolsk

Date of registration: 2002

Founders: Shareholding company PAO"Tampo", Mirilashvili Mikhail Mikhailovich, Panikashvili David Isaakovich, Zeitlin Oleg Yakovlevich, Strepetov Vadim Valentinovich, Shepel Boris Albertovich, Semenyuk Alexander Vasilievich, Konev Oleg Yurievich.

The president: Panikashvili David Isaakovich

• Authorized capital: 1,000,000 rubles
• Fixed assets: 621,356 thousand rubles
• Revenue:RUB 63,384,563 thousand
• Accounts receivable: RUB 18,293,282 thousand
• Accounts payable: 35,244,901 thousand rubles
• Net profit: 415,314 thousand rubles
• Net assets: RUB 1,755,002 thousand
• TIN - 7726320638

Sources: official website: rostagroup.ru, extract from the Unified State Register of Legal Entities, Rosstat (data of financial statements under RAS for 2015).

Protek

Closed joint-stock company firm "Introduction Center" Protek ". The Protek group of companies is engaged in the production, distribution and retail through drugstore chains.

The production and technological capacities of the holding comply with GMP standards.

Legal address: Moscow city

Date of registration: 1994

Founders: JSC "Protek"

CEO: Pogrebinsky Dmitry Borisovich

• Authorized capital: 40,000,000 rubles
• Fixed assets: 1,082,865 thousand rubles.
• Revenue: 166,578,310 thousand rubles
• Accounts receivable: 32,742,113 thousand rubles.
• Accounts payable: 69,059,867 thousand rubles
• Net profit: RUB 5,419,719
• Net assets: 8,094,159 rubles
• TIN - 7724053916

Sources of information: official website of the company: http://www.protek-group.ru, extract from the Unified State Register of Legal Entities, Rosstat (data of financial statements according to RAS for 2015).

Quatrain

The geography of work "Katren" covers 85 subjects of the Russian Federation, delivers more than 18 thousand types of pharmaceutical products.

Legal address: city ​​Novosibirsk

Date of registration: 1993

Founders: Konobeev Leonid Valentinovich, Spiridonov Vladimir Nikolaevich

CEO: Konobeev Leonid Valentinovich

• Authorized capital: 1 billion 500 million rubles
• Fixed assets: 6,752,880 thousand rubles
• Revenue: 182,301,551 thousand rubles
• Accounts receivable: 30,155,368 thousand rubles.
• Accounts payable: 65,656,588 thousand rubles
• Net profit: 5,790,742 thousand rubles
• Net assets: RUB 11,103,940 thousand
• TIN - 5408130693

Sources: official website: http://katren.ru, extract from the Unified State Register of Legal Entities, Rosstat (data of financial statements according to RAS for 2015).

View information about the project

When you buy a product or service from someone, you give him money for development, finance him (help). Without buying - do not help (do not finance). By buying Russian goods and services, you are helping Russian people. This is reasonable for you if you are part of the Russian people.

Dmitry Mezentsev

Follow RUSSIAN SOYUZRF @russkii_souz

The information you add must meet our selection criteria

• Russian manufacturers- these are Russian owners of production, producing goods on the territory of their country, registered in it and using the labor of Russian workers. Accordingly, they produce Russian goods.
• Russian owners or co-owners of production, using something foreign in the production process (companions, employees, territory, etc.) are placed in the section "Production with Russian participation". Accordingly, they produce goods with Russian participation.
• Russian sellers- These are Russian entrepreneurs who use the labor of Russian workers and sell Russian goods or goods with Russian participation. If the store has at least one shelf with Russian goods, then the store can be placed in the catalog and advertise these goods.
• Russian services provided by Russian entrepreneurs who use the labor of Russian workers and seek, if possible, to use Russian goods.

Also be sure to check out

JSC "VERTEX" (St. Petersburg)
Production of finished dosage forms and parapharmaceuticals. The assortment portfolio of the company includes more than 200 items. In 2015, a new production site was opened with a design capacity of more than 100 million packages per year.

CJSC "Biocad" (St. Petersburg, Moscow region)
Production of drugs for the treatment of infectious, viral, autoimmune and oncological diseases. Production sites are located on the territory of St. Petersburg and the Moscow region. The product portfolio includes 45 items.

GEROPHARM group of companies (St. Petersburg, Moscow region)
Production of biotechnological drugs based on genetic engineering technologies, including insulin analogs, as well as other drugs for the treatment of socially significant diseases. There are 10 medicines in the product portfolio.

OOO NTFF POLYSAN (St. Petersburg)
Development and introduction into medical practice of drugs of our own production. The company produces original drugs: Cycloferon, Reamberin, Cytoflavin and Remaxol.

OOO Novartis Neva (St. Petersburg)
The first plant of the Novartis group of companies in Russia. The planned production capacity is 1.5 billion units of solid dosage forms per year.

LLC "Grotex" (Solopharm) (St. Petersburg)
Specialization in the production of liquid sterile dosage forms. The Solopharm plant was put into operation in 2013. The design capacity is more than 1 billion units per year.

CJSC "Active Component" (St. Petersburg)
Production of active pharmaceutical ingredients. More than 30 types of API.

LLC "NPF "KEM" (St. Petersburg)
Industrial chemical synthesis of drug substances. Substances: Dioxidine, Diazolin, Arbidol, Meldonium, Pantogam, Proxadolol, etc.

SKTB "Tekhnolog" (St. Petersburg)
Production of TOC products, composite materials and devices, medicinal substances, polymer compositions

PJSC Pharmsintez (St. Petersburg)
Production of fine organic synthesis products (TOS) and active pharmaceutical ingredients (API).

LLC "Pharmamed" (St. Petersburg)
Release of FPP (Nitroglycerin, Valemidin); Production of active pharmaceutical ingredients (unithiol, iodantipyrine, ethylmethylhydroxypyridine succinate, etc.)

Group of companies Pik-Pharma (St. Petersburg-Belgorod)
Production of substances and finished medicines. The company has three production sites. There are 13 drugs in the product portfolio.

MBNPK "Cytomed" (St. Petersburg-Finland)
Production of peptide drugs. Production sites in St. Petersburg and Lappeenranta.

JSC "Pharmaceutical factory of St. Petersburg" (St. Petersburg)
Development, production and sale of medicinal products from plant materials

OOO "Samson-Med" (St. Petersburg)
Production is carried out according to following directions: injection forms; infusion solutions; natural hormonal and enzyme preparations.

CJSC "Northern Star" (Leningrad region, Kuzmolovsky village)
Production of solid dosage forms: tablets and coated tablets, hard gelatin capsules. The assortment portfolio is about 40 items.

CJSC "Pharmproekt" (St. Petersburg)
Manufacture of finished medicines.

LLC "Alcor Bio" (St. Petersburg)
Development, production and sale of kits for enzyme immunoassay

Pharmacor Production LLC (St. Petersburg)
Production of a wide range of medicines, dietary supplements, as well as packaging production of drugs from leading European companies.

JSC "Medpolimer" (St. Petersburg)
Manufacture of medicines, medical devices and products for dentistry.

LLC "Biotech" (St. Petersburg)
Isolation and purification of recombinant human interleukin-2

OJSC "Pharmstandard" (Moscow)
The company produces more than 200 types of finished medicines. The largest domestic holding

Federal State Unitary Enterprise NPO Microgen of the Ministry of Health of the Russian Federation (Moscow)
Development and production of immunobiological, diagnostic and medicinal preparations

JSC "Veropharm" (Moscow)
Production of generics, oncological drugs, medical patches.

NPO PETROVAKS PHARM (Moscow)
Production of original drugs Polyoxidonium, Longidaza, Grippol.

CJSC PharmFirma Sotex (Moscow)
The company's product portfolio includes 67 medicines, including 28 of its own.

JSC "Valenta Pharmaceutics" (Moscow region)
Production of solid dosage forms, as well as the production of neurological and antimicrobial drugs

KRKA-RUS LLC (Moscow region, Istra)
Production of drugs for the treatment of cardiovascular diseases.

OAO "Akrikhin" (Moscow)
Production of FPP, the company produces about 150 types of drugs

LLC "Alcoy" (Moscow)
Development and production of homeopathic drugs, medical cosmetics and dietary supplements

Joint-Stock Company "Partner" (Moscow)
Development and production of immunobiological preparations, dietary supplements and food products for the treatment of dysbacteriosis

CJSC "Moscow Pharmaceutical Factory" (Moscow)
Manufacture of tinctures, extracts, ointments, syrups, homeopathic preparations, medicinal spirits...

JSC "Moskhimfarmpreparaty named after N.A. Semashko" (Moscow)
Production of drugs of various pharmacotherapeutic groups, production of drugs.

CJSC "ECOlab" (Moscow region, Elektrogorsk)
Production of ELISA test systems and other diagnostic MIBP, kits for biochemical, hematological, histological and general clinical laboratory studies, as well as FPP.

JSC "Nizhpharm" (Nizhny Novgorod)
It is part of the STADA CIS holding. Production is located on almost 11.5 thousand square meters. meters with workshops for the production of ointments, creams, suppositories, liniments, tablets.

OAO Tatkhimfarmpreparaty (Kazan)
It has two modern plants: a chemical-pharmaceutical plant and a plant for suture-surgical materials. production facilities, allowing to annually produce more than 111 types of finished medicines.

OAO Kurgan Sintez (Kurgan)
Production of substances of natural and semi-synthetic antibiotics, production of OTC drugs and honey. plastic products.

CJSC "Evalar" ( Altai region Biysk)
Development and production of natural medicines and parapharmaceuticals

CJSC "Altaivitaminy" (Altai Territory, Biysk)
A large manufacturer of medicines, dietary supplements on a natural basis, fortified food products and cosmeceuticals

JSC "Biosintez" (Penza)
Production of various pharmaceutical products

JSC "Novosibkhimfarm" (Novosibirsk)
Specializes in the production of injection solutions in ampoules and patches.

LLC NPO "SibEnzim" (Novosibirsk)
Manufacture and sale of enzymes for the metabolism of nucleic acids and related drugs.

JSC "Biochemist" (Saransk)
Produces more than 60 types of drugs: antibiotics, anticancer drugs, plasma-substituting solutions, diuretics, drugs used for anesthesia, painkillers

JSC "Kraspharma" (Krasnoyarsk)
Main products - antibiotics, infusions and blood plasma substitutes

JSC "Organika" (Novokuznetsk)
GLS release. The main products are medicines acting on the central nervous system.

OJSC Pharmasyntez (Irkutsk)
The largest domestic manufacturer of anti-tuberculosis drugs in the country. Included in the top twenty pharmaceutical companies Russia in terms of production

It can be said without exaggeration that providing citizens with medicines and preparations is an important component of the national security of the state. Pharmaceutical production is the most important socially significant branch of the economy.

Government support

To date, the social significance of such products as pharmaceuticals, the production of which has been established on the territory of our country, has reached such a level that the government is forced to pay serious attention to projects involving the development of this industry. It should be noted that in recent years a number of policy documents have been adopted that contribute to the organization and development of production, including pharmaceutical substances, but the situation in this area still does not inspire optimism, and here is why.

Important features of the industry

Pharmaceutical production has its own characteristics. They are presented:

• high science intensity of products;
• a significant duration of the process of developing new medicinal components, as well as corresponding drugs;
• lengthy life cycle drugs, including all stages - development, production and sale of products;
• nature and duration production cycle required for release finished products;
• a wide variety of species technological processes, which are used in such an area as the production of pharmaceutical substances;
• a wide variety of raw materials and materials, as well as equipment used in the production cycle;
• multi-stage technological processes.

Investment

From the point of view of a potential investor, the production of pharmaceutical products has a number of distinguishing features. And the main negative points that you should pay attention to are as follows:

1. Higher investment attractiveness of the production of finished products, that is, drugs, in comparison with the production of medicinal substances. This trend has been shaped by modern economic conditions. The explanation for this fact can be the high material and energy intensity of the production of standardized semi-finished products, which led to a decrease in the profitability of their production, and sometimes to the unprofitability of such production.
2. Rising cost material resources in Lately, which caused a significant increase in the cost of substances produced in our country. The consequence of this - on them to a level exceeding the world. Such trends have led to the fact that the pharmaceutical industry has become unable to offer competitive products.
3. Providing foreign manufacturers easy access to the pharmaceutical market of our country. This has created tremendous competition for every domestic manufacturer, which in most cases is not able to resist the active expansion of inexpensive substances of low quality to the domestic market.

The main trends of the pharmaceutical market

According to some estimates, the volume of the pharmaceutical market, according to the results of recent years, in our country reaches 1 trillion rubles. At the same time, domestic medicines in the total volume products sold of this type make up only about 25% in monetary terms and approximately 60% in kind.

burning questions

Today, one of the most pressing issues that worries those interested in the development of domestic pharmaceutical production is the origin of standardized semi-finished products, which are the basis for the production of finished drugs on the territory of our state. Unfortunately, the conclusions of experts do not inspire optimism for domestic producers. Pharmaceutical production of medicinal components in our country is practically not developed.

Import of pharmaceutical substances

As for imports, in recent years a situation has developed when about 80% of the volume of imported pharmaceutical substances in monetary terms is occupied by Germany, France, Italy and China.

It is noteworthy that, when considering the natural expression of import volumes, completely different figures are obtained. Yes, his the largest share today is China - it is more than 70% of the total volume. Considering the ratio of specific shares calculated according to physical and cost indicators, we can conclude that the substances produced in the named country are characterized by a significantly lower price compared to similar products from other countries.

What is imported

Imports mainly include components of well-known drugs for a long time, represented by acetylsalicylic acid, paracetamol, metamizole sodium, metformin, ascorbic acid and other drugs that are in demand among the population mainly due to low cost.

Says that the share of production domestic enterprises characterized by a negligible figure, 8-9% of the total pharmaceutical market.

conclusions

Probably, the above facts make it possible to assert the obviousness of the need to restore the production volumes of the products in question. The technology of pharmaceutical production of substances should be restored and applied in full. The development of this sphere is necessary first of all in order to ensure the national security of the state.

Such statements are not empty words at all. Many manufacturers are faced with the fact of providing the domestic economy with substances from foreign suppliers on a residual basis. And this cannot but cause concern.